𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined treatment with pegylated interferon–α-2a and dacarbazine in patients with advanced metastatic melanoma : A phase 2 study

✍ Scribed by Axel Hauschild; Reinhard Dummer; Selma Ugurel; Katharina C. Kaehler; Friederike Egberts; Wolfram Fink; Jeannine Both-Skalsky; Barbara Laetsch; Dirk Schadendorf

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
105 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Temozolomide in combination with interfe
Temozolomide in combination with interferon α-2b in patients with metastatic melanoma : A Phase I dose-escalation study
✍ Sanjiv S. Agarwala; John M. Kirkwood 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND Metastatic melanoma (MM) is associated with a high risk of central nervous system (CNS) metastases, and current chemotherapy does not adequately treat or protect patients with MM against CNS metastases. Therefore, the authors initiated a Phase I study to determine the pha

A Phase II study of “decrescendo” interl
A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy
✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

Induction of tyrosinase-reactive T cells
Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha ± interleukin-2 in patients with metastatic melanoma
✍ Alexander Schmittel; Ulrich Keilholz; Regina Max; Eckhard Thiel; Carmen Scheiben 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 92 KB 👁 2 views

We have shown the presence of tyrosinase-reactive T cells in the peripheral blood of melanoma patients, who had been in remission after treatment with IL-2-containing regimens. In this consecutive study, we analyzed the T-cell response to various peptides derived from tyrosinase in serial blood samp